Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.

摘要: Abstract Background Scarce data are available about safety and efficacy of cetuximab in elderly metastatic colorectal cancer (mCRC) patients. Patients methods We retrospectively analysed 54 irinotecan-refractory mCRC patients aged≥70 years treated with plus irinotecan evaluated clinical outcome according to KRAS BRAF mutational status. Results Median age was 73 (70–82). Main grade 3–4 toxicities were skin rash (15%), diarrhea (19%) neutropenia (13%). Irinotecan dose reduction necessary 39% Fifty-two (96%) for The 29 wild-type achieved better RR (31% vs 4%; p =0.030) median PFS (4.21 months 3.95 months; =0.034; HR: 0.50, 95% CI: 0.27–0.95) when compared mutated ones. (41% 3%; =0.001) mPFS (4.57 3.78 months, =0.001; 0.35, 0.19–0.66) significantly higher among the 22 30 or Conclusion Cetuximab has a favourable profile patients, but reduced should be considered. Such combination can useful option